GLF
ZVRA icon

Groupe la Francaise’s Zevra Therapeutics ZVRA Stock Holding History

Groupe la Francaise’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-242
Closed -$1.97K – 798
2025
Q3 		$1.97K Buy
+242
New +$2.43K ﹤0.01% 717

Other funds holding ZVRA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Groupe la Francaise's ZVRA Position: Q4 2025 in Review

Groupe la Francaise sold out of Zevra Therapeutics (ZVRA) in Q4 2025, closing a stake of 242 shares — an estimated $1.97K sold.

Groupe la Francaise first reported a position in ZVRA in Q3 2025 and held it in 1 quarter. The position peaked at $1.97K in Q3 2025. 158 funds tracked by Wall St. Rank hold ZVRA as of Q4 2025.

  • Groupe la Francaise reported no remaining Zevra Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Groupe la Francaise sold 242 Zevra Therapeutics shares in Q4 2025, an estimated $1.97K.
  • Groupe la Francaise first reported a position in Zevra Therapeutics in Q3 2025 and held it in 1 quarter.
  • Groupe la Francaise's Zevra Therapeutics position peaked at $1.97K in Q3 2025.
  • 158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2025.

Based on Groupe la Francaise's 13F filing for Q4 2025, filed 12 Feb 2026.